

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC20170001884		Fecha de prioridad: 15 de agosto de 2014		
CRITERIOS PARA LA BÚSQUEDA				
Palabras clave utilizadas		polimorfos AND selinexor		
		(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)- 1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide		
		(polymorphs OR crystalline OR form) AND or CRM1		
		(polymorphs OR crystalline OR form) AND (1,2,4-triazol-1-yl-N-pyrazin)		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07D403/12, A61K31/497, A61P35/00, A61P25/00, A61P31/00		
DOCUMENTOS CONSIDERADOS RELEVANTES				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	Ninguna	---	---	---
ISA/IPEA (EPO) Espacenet	WO2011109799	09/09/2011	---	A
	WO2013019548	07/02/2013	1 – 72 (Ej 2, págs. 11, 56, 97)	X
	"Advanced Organic Chemistry", March, 4th ed. McGraw Hill (1992) or, "Organic Synthesis", Smith, McGraw Hill, (1994)	1994	1 – 72	Y
USPTO	No han			
	buscado			
Patbase	Ninguna	---	---	---
Google Patents	Ninguna	---	---	---
EPOQUE	Ninguna	---	---	---
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Fecha del reporte de búsqueda:

de de 201



Menu ▾

Search ▾

History ▾

Session ▾

Folder ▾

Order

Help ▾

Logoff

#	Search query	Results	Options
3	STAC=((polymorphs OR crystalline OR form) AND selinexor)	8	View Browse Hits Optimise more...
2	STAC=((polymorphs OR crystalline OR form) AND selinexor) and IC=(A61K31/497)	4	View Browse Hits Optimise more...
1	STAC=((Z)-3-(3-(3, 5-bis (trifluoromethyl)phenyl)- 1H-1, 2, 4-triazol-1-yl)-N'-(pyrazin-2-yl) acrylohydrazide)	0	



(polymorphs OR crystalline OR form) AND selinexor



Todo Noticias Imágenes Vídeos Más Preferencias Herramientas

Cerca de 108 resultados (0,32 segundos)

Polymorphs of selinexor

www.google.com.co/patents/EP3180331A1?cl=en - Traducir esta página

Solicitud - Presentada el 14/08/2015 - Publicada el 21/06/2017 - Brian Clinton AUSTAD - Karyopharm Therapeutics, Inc.

Selinexor has the chemical structure shown in Structural Formula I: and is also referred to herein as KG8. [0006] In one embodiment, a single **crystalline form** of a ...

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Polymorphs of selinexor

www.google.com.co/patents/WO2016025904A1?cl=en - Traducir esta página

Solicitud - Presentada el 14/08/2015 - Publicada el 18/02/2016 - Brian Clinton AUSTAD - Karyopharm Therapeutics Inc.

[0006] In one embodiment, a single **crystalline form** of a compound represented by Structural Formula I is provided, wherein the single **crystalline form** is **Form A**.

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Solid forms of selinexor and process for their preparation

www.google.com.co/patents/WO2017118940A1?cl=en - Traducir esta página

Solicitud - Presentada el 6/01/2017 - Publicada el 13/07/2017 - Ramanaiah CHENNURU - Dr. Reddy's Laboratories Limited

Specific aspects relate to **crystalline** and amorphous forms of **Selinexor**. ... WO

2016025904 A1 discloses various **crystalline** forms of **Selinexor** namely **Form A**, **Form B**, **Form C**, **Form D**, compositions and MoU thereof for the ... **polymorphs** ...

[Descripción general](#) · [Información relacionada](#) · [Debatir](#)

Easy search					Save strategy			
Menu Filter Explorer					11 results for ((polymorphs OR crystalline OR form) AND selinexor)/CLMS - Collection: FAMPAT			
Filter options					Display			
1st application year					#	Title	Publ. date	Publication number
After 2015	(7)	1			1	Solid forms of selinexor and process for their preparation	2017-07-13	WO2017118940
2011-2015	(4)	2			2	Novel crystalline forms of selinexor and process for their preparation	2018-07-12	WO2018129227
2006-2010	(0)	3			3	Solid forms of selinexor and process for their preparation	2017-11-17	IN201641000711
2001-2005	(0)	4			4	2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof	2016-02-03	CN105294736
Before 2001	(0)	5			5	Substituted urea derivatives and pharmaceutical uses thereof	2016-01-21	CA2952083
Legal status					6	Compositions for ileo-jejunal drug delivery	2016-06-30	WO2016105582
Alive	(11)	7			7	Improved processes for the preparation of selinexor	2017-11-10	IN201641015422
Dead	(0)	8			8	Ccr2 modulators	2016-11-24	CA2985194
Assignee					9	Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them	2016-08-11	US20160228455
IPC classification					10	Combination therapies	2017-12-28	WO2017223422
		11			11	Viral resistant cells and culture systems	2018-08-02	WO2018140478
							2015-07-23	78 %
							2015-07-16	78 %
							2015-12-23	60 %
							2016-05-03	59 %
							2016-05-19	47 %
							2015-02-09	33 %
							2017-06-23	29 %
							2018-01-24	19 %


L1		COUNTS	RESULTS
		CAplus (62)	REGISTRY (232)
		INPADOC (4)	PCTFULL (2)
		USFULL (0)	
		Sort by: Publication Date	
		Display: 25	
		1. WOA1 (2018) NOVEL CRYSTALLINE FORMS OF SELINEXOR AND PROCESS FOR THEIR PREPARATION	
		The present disclosure relates to solid state forms of Selinexor , processes for preparation thereof and pharmaceutical compositions thereof.	
		2. WOA1 (2017) SOLID FORMS OF SELINEXOR AND PROCESS FOR THEIR PREPARATION	
		Aspects of the present application relate to solid forms of Selinexor , processes for their preparation and pharmaceutical compositions thereof. Specific aspects relate to crystalline and amorphous forms of Selinexor .	

1/1 © EPODOC / EPO

TI - Hydrazide containing nuclear transport modulators and uses thereof

PN - [NZ719623 A](#) 20171222

AB - The disclosure relates to a method for treating a veterinary subject suffering from cancer, comprising administering to said veterinary subject a therapeutically effective amount of a compound represented by (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)**acrylohydrazone**, or a pharmaceutically acceptable salt thereof. The subject can be a dog and the cancer can be lymphoma. Also disclosed is family of nuclear transport modulators (CRM1 inhibitors). The disclosure also relates to the use these compounds for the treatment of disorders such as proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, cancer and a respiratory disorder and methods of manufacturing these compounds.



[SS 7] TRIAZOL 7D acrylohydrazone

Results in EPODOC 1

[SS 8] ..LI PN TI AB




1/1 © EPODOC / EPO

PN - [NZ719623 A](#) 20171222

TI - Hydrazide containing nuclear transport modulators and uses thereof

AB - The disclosure relates to a method for treating a veterinary subject suffering from cancer, comprising administering to said veterinary subject a therapeutically effective amount of a compound represented by (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyridin-2-yl)**acrylohydrazone**, or a pharmaceutically acceptable salt thereof. The subject can be a dog and the cancer can be lymphoma. Also disclosed is family of nuclear transport modulators (CRM1 inhibitors). The disclosure also relates to the use these compounds for the treatment of disorders such as proliferative disorder, an inflammatory disorder, an autoimmune disorder, a viral infection, an ophthalmological disorder, a neurodegenerative disorder, a disorder of abnormal tissue growth, a disorder related to food intake, allergies, cancer and a respiratory disorder and methods of manufacturing these compounds.



[SS 8] |